Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wen-Shuo, Chen, Yuh-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263962/
https://www.ncbi.nlm.nih.gov/pubmed/25563355
http://dx.doi.org/10.3390/jpm4030297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263962/
https://www.ncbi.nlm.nih.gov/pubmed/25563355
http://dx.doi.org/10.3390/jpm4030297

Ejemplares similares